Discounted Cash Flow (DCF) Analysis Levered

Celularity Inc. (GXGX)

$ 10.2
2.18 27.18%

Free Cash Flow

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue -------
Revenue (%)
Operating Cash Flow -------
Operating Cash Flow (%)
Capital Expenditure -------
Capital Expenditure (%)
Free Cash Flow -------

Weighted Average Cost Of Capital

Share price $ 10.2
Beta 0.000
Diluted Shares Outstanding 8.02
Cost of Debt
Tax Rate 7.86
After-tax Cost of Debt 4.61%
Risk-Free Rate
Market Risk Premium
Cost of Equity 2.460
Total Debt -
Total Equity 81.76
Total Capital 81.76
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue -------
Operating Cash Flow -------
Capital Expenditure -------
Free Cash Flow -------
WACC
PV LFCF -------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 2.46
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -0
Equity Value -
Shares Outstanding 8.02
Equity Value Per Share -